BACKGROUND: There is increasing concern that the use of second-generation antipsychotic medications in schizophrenia is associated with the development of metabolic syndrome. AIMS: This study assessed the prevalence and clinical associations of metabolic syndrome among patients receiving clozapine within the catchment area of a mental health service in the west of Ireland. METHOD: A total of 84 patients (96% response rate) taking clozapine were interviewed and thoroughly investigated using physical assessments, comprehensive laboratory testing and review of medical records. RESULTS: Of the patients, 46.4% taking clozapine fulfilled the criteria for metabolic syndrome. Male gender, high body mass index, high insulin level and receiving a concomitant antipsychotic medication were significantly associated with the presence of metabolic syndrome. CONCLUSION: Almost half of the patients receiving clozapine have metabolic syndrome and are consequently at risk of cardiovascular morbidity and mortality. Such patients should be closely monitored in order to facilitate interventions, which could alleviate the adverse health consequences of this syndrome.
BACKGROUND: There is increasing concern that the use of second-generation antipsychotic medications in schizophrenia is associated with the development of metabolic syndrome. AIMS: This study assessed the prevalence and clinical associations of metabolic syndrome among patients receiving clozapine within the catchment area of a mental health service in the west of Ireland. METHOD: A total of 84 patients (96% response rate) taking clozapine were interviewed and thoroughly investigated using physical assessments, comprehensive laboratory testing and review of medical records. RESULTS: Of the patients, 46.4% taking clozapine fulfilled the criteria for metabolic syndrome. Male gender, high body mass index, high insulin level and receiving a concomitant antipsychotic medication were significantly associated with the presence of metabolic syndrome. CONCLUSION: Almost half of the patients receiving clozapine have metabolic syndrome and are consequently at risk of cardiovascular morbidity and mortality. Such patients should be closely monitored in order to facilitate interventions, which could alleviate the adverse health consequences of this syndrome.
Authors: Stephen R Marder; Susan M Essock; Alexander L Miller; Robert W Buchanan; Daniel E Casey; John M Davis; John M Kane; Jeffrey A Lieberman; Nina R Schooler; Nancy Covell; Scott Stroup; Ellen M Weissman; Donna A Wirshing; Catherine S Hall; Leonard Pogach; Xavier Pi-Sunyer; J Thomas Bigger; Alan Friedman; David Kleinberg; Steven J Yevich; Bonnie Davis; Steven Shon Journal: Am J Psychiatry Date: 2004-08 Impact factor: 18.112
Authors: Deanna L Kelly; Robert P McMahon; Fang Liu; Raymond C Love; Heidi J Wehring; Joo-Cheol Shim; Kimberly R Warren; Robert R Conley Journal: J Clin Psychiatry Date: 2010-01-12 Impact factor: 4.384
Authors: Marius H Sneller; Nini de Boer; Sophie Everaars; Max Schuurmans; Sinan Guloksuz; Wiepke Cahn; Jurjen J Luykx Journal: Front Psychiatry Date: 2021-03-29 Impact factor: 4.157
Authors: Kevin McCarthy; Eamon Laird; Aisling M O'Halloran; Padraic Fallon; Deirdre O'Connor; Román Romero Ortuño; Rose Anne Kenny Journal: PLoS One Date: 2022-09-14 Impact factor: 3.752